



Vineet Laboratories Limited

Regd. Office: SY. No. 11/A3, Saheb Nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar Hyderabad.
CIN- L24304TG2016PLC112888
Phone: 040-24128833; Email Id: cs@vineetlabs.co.in; Website: vineetlabs.co.in

November 08, 2025

To
The General Manager,
Department of Corporate Services,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai-400 001.

To
The Manager,
Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No – C/1,
G Block, Bandra Kurla Complex,
Bandra (East), Mumbai -400 051.

Scrip Code – 543298

Scrip Code - VINEETLAB

Dear Sir/Ma'am,

Sub: Outcome of Board Meeting held on Saturday, November 08, 2025 as required under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors of the company in its meeting held today i.e., Saturday, November 08, 2025 has:

- considered and approved the unaudited standalone financial results of the company for the Second quarter and the half year ended on September 30, 2025 along with the Limited Review Report submitted by the Statutory Auditors.
- based on the recommendation of Nomination and Remuneration Committee - unanimously approved the appointment of Ms. Jasmin Kunal Tailor (DIN: 10794164) as an Additional Non-Executive Independent Director for a term of 3 (Three) consecutive years with effect from 9th November 2025 to 8th November 2028, subject to the subsequent approval of the shareholders of the company.
- noted the resignation of Ms. Hari Priya Yerukalapudi (DIN:09690829) from the office of Independent Director w.e.f the close of business hours of 8th November, 2025.
- based on the recommendation of Nomination and Remuneration Committee - revised the remuneration of Mr. Gaddam Venkata Ramana (DIN: 00031873), Managing Director of the Company, subject to the approval of the shareholders.
- based on the recommendation of Nomination and Remuneration Committee - revised the remuneration of Mr. Satyanarayana Raju Bhupathiraju (DIN:02697880), Whole Time Director and CFO of the Company, subject to the approval of the shareholders.

Please find enclosed:

- the unaudited Standalone financial results under IndAS for the quarter ended September 30, 2025, together with the Limited Review Report.
- the details that need to be disclosed w.r.t appointment of Director under Regulation 30 of SEBI (LODR) Regulations read with SEBI Circular No. SEBI/ HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are mentioned in Annexure 1.



Vineet Laboratories Limited

Regd. Office: SY. No. 11/A3, Saheb Nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar Hyderabad.

CIN- L24304TG2016PLC112888

Phone: 040-24128833; Email Id: cs@vineetlabs.co.in; Website: vineetlabs.co.in

- the letter of resignation (Annexure 2) along with detailed reasons for the resignation. In addition, the details that need to be disclosed w.r.t the resignation of Independent Director under Regulation 30 SEBI (LODR) Regulations read with SEBI Circular No. SEBI/ HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are mentioned in Annexure 2.

The financial results are also being made available on the Company's website at www.vineetlabs.co.in and also on the websites of BSE Limited and National Stock Exchange of India.

The Board Meeting commenced at 12:00 Noon and concluded at 04:10 PM.

Kindly take this information on records.

Thanking you,
Best Regards,

For Vineet Laboratories Limited

Gaddam Venkata Ramana
Managing Director
DIN: 00031873





Vineet Laboratories Limited

Regd. Office: SY. No. 11/A3, Saheb Nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar Hyderabad.

CIN- L24304TG2016PLC112888

Phone: 040-24128833; Email Id: cs@vineetlabs.co.in; Website: vineetlabs.co.in

Annexure 1

Appointment of Ms. Jasmin Kunal Tailor (DIN: 10794164) as a Non-Executive Independent Director of the Company

S. No	Particulars	Description
1.	Name in Full	Jasmin Kunal Tailor (DIN: 10794164)
2.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Ms. Jasmin Kunal Tailor (DIN: 10794164) as a Non-Executive Independent Director for a term of 3 (Three) consecutive years with effect from 9 th November 2025 to 8 th November 2028 (both days inclusive), subject to the subsequent approval of the shareholders in the next General Meeting or within three months from the date of appointment, whichever is earlier.
3.	Date of Appointment/Resignation/Cessation	9 th November 2025
4.	Brief Profile	She is a B.Com graduate from Mumbai University. And is a seasoned retail executive with over 10 years of experience in management, strategic growth, and business development. She excels at aligning operational efficiency with brand value, having led initiatives that boosted customer engagement, market expansion, and profitability. Her leadership across various retail roles has shaped sales strategies, optimized performance, and driven consistent revenue growth.
5.	Disclosures of relationships between Directors	She is not related to any Director of the company.
6.	Information as required under circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/24 dated June 20, 2018 issued by BSE and NSE respectively.	Not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority.
7.	Disclosure of holding of securities of the company as on the date of appointment as key managerial personnel or a director of the company or becoming a promoter as per Regulation 7(1) of SEBI (Prohibition of Insider Trading) Regulations, 2015	Nil



Vineet Laboratories Limited

Regd.Office: SY. No. 11/A3, Saheb Nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar Hyderabad.
CIN- L24304TG2016PLC112888
Phone: 040-24128833; Email Id: cs@vineetlabs.co.in; Website: vineetlabs.co.in

Annexure 2

Details of resignation of Ms. Hari Priya Yerukalapudi (DIN: 09690829), Independent Director

S.No	Particulars	Description
1.	Name in Full	Ms. Hari Priya Yerukalapudi (DIN: 09690829)
2.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Resignation
3.	Date of Appointment/Resignation	w.e.f. close of business hours of 8 th November, 2025
4.	Brief Profile (In case of appointment)	Not Applicable
5.	Disclosures of relationships between Directors (In case of appointment of Director)	Not Applicable

LETTER OF RESIGNATION

Date: November 07, 2025

To
The Board of Directors,
Vineet Laboratories Limited.

Dear Board Members,


Sub: Resignation from the position of independent director

Because of change in my professional priorities and family necessities, I hereby tender my resignation from the independent directorship of the Company. Kindly accept my resignation with effect from closing of business hours of November 08, 2025.

Moreso, I sincerely thank all the Directors for extending their co-operation and support in discharging my duties during my tenure as an independent director. My best wishes are with the company and its management in all its future endeavours.

Moreover, I hereby declare that I am not a Director in any other listed Company. Also, there are no other material reasons for my resignation other than those mentioned in this letter.

You are requested to acknowledge the receipt of resignation and file the documents required both with the Registrar of Companies and the Stock Exchanges and do share a copy of the acknowledgment of the same with me.


Hari Priya Yerukalapudi
DIN: 09690829

VINEET LABORATORIES LIMITED
CIN:L24304TG2016PLC112888

SY . No. 11/A3, Saheb nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana-500074, India.

Statement of Unaudited Financial Results for the Quarter and half year ended September 30,2025

(All amounts are in INR Lakh except share data or unless otherwise stated)

S No	Particulars	Quarter ended	Quarter ended	Quarter ended	Half year ended	Half year ended	Year ended
		September 30, 2025	June 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024	March 31, 2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Income from operations						
	a) Net Sales/income from operations	1,741.95	744.18	1,895.76	2,486.13	4,261.93	7,499.50
	Total income from operations	1,741.95	744.18	1,895.76	2,486.13	4,261.93	7,499.50
II	Other income	0.84	1.81	20.02	2.65	57.28	198.68
III	Total Income (I + II)	1,742.79	745.98	1,915.78	2,488.78	4,339.20	7,698.18
VI	Expenses						
	a) Cost of materials Consumed	1,708.95	1,200.92	1,625.46	2,909.87	3,299.34	6,376.84
	b) Changes in inventories of finished goods, work-in progress and stock-in-trade (increase)/decrease	-527.33	(739.72)	(281.50)	(1,267.05)	(59.40)	647.00
	c) Employee benefits expenses	79.65	105.96	129.43	185.61	277.25	533.58
	d) Finance cost	218.70	61.22	98.98	279.92	212.63	397.76
	e) Depreciation and amortisation expenses	62.54	62.54	61.65	125.08	122.51	250.16
	f) Other expenses	163.12	145.23	453.04	308.34	874.92	1,570.39
	Total expenses	1,705.63	836.14	2,087.05	2,541.77	4,727.24	9,775.73
V	Profit/(loss) before exceptional items and tax (III - IV)	37.16	(90.16)	(171.27)	(53.00)	(388.04)	(2,077.55)
VI	Exceptional items	-	-	-	-	-	-
VII	Profit/(loss) before Tax (V - VI)	37.16	(90.16)	(171.27)	(53.00)	(388.04)	(2,077.55)
VIII	Tax expense :						
	a. Current tax (net)	-	-	-	-	-	-
	b. Deferred tax (net)	-2.94	(3.55)	11.57	(6.49)	7.88	(58.45)
	Total tax expense	(2.94)	(3.55)	11.57	(6.49)	7.88	(58.45)
IX	Profit/(loss) for the period (VII-VIII)	40.10	(86.61)	(182.84)	(46.51)	(395.91)	(2,019.10)
X	Other comprehensive income(OCI)						
	a) (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	15.29
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	(3.85)
	b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other comprehensive income/(loss)	-	-	-	-	-	11.44
XI	Total comprehensive income/(loss) net of tax for the Period/year (IX+X)	40.10	(86.61)	(182.84)	(46.51)	(395.91)	(2007.67)
XII	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	921.90	921.90	921.90	921.90	921.90	921.90
XIII	Other equity						542.86
XIV	Earnings per equity share (of Rs. 10/- each) : (not annualised for the quarters)						
	(i) Basic	0.43	(0.94)	(1.98)	(0.50)	(4.29)	(21.90)
	(ii) Diluted	0.43	(0.94)	(1.98)	(0.50)	(4.29)	(21.90)

Notes

a) The above statement of unaudited financial results of Vineet Laboratories Limited ("the Company"), which have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI") were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on November 8th, 2025. The Statutory Auditors have issued an unqualified report thereon.

b) The company operates in one reportable business segment i.e. Active pharmaceuticals ingredient and intermediates. Hence segmental reporting as per Ind AS 108 is not applicable.

c) The results for the quarter and half year ended 30th September, 2025 are also available on website of BSE Limited, NSE Limited and on the Company's website.

d) Figures for the previous periods have been rearranged/ reclassified wherever necessary to conform to the current period presentation.

For and on behalf of the Board

Date 08.11.2025
Place : Hyderabad.



G. Venkata Ramana
Managing Director
DIN: 00031873

Vineet Laboratories Limited
CIN:L24304TG2016PLC112888

Balance sheet for the period ended 30 September 2025

(All amounts are in INR Lakhs except share data or unless otherwise stated)

	As at	
	30 September 2025	31 March 2025
ASSETS		
Non-current assets		
(a) Property, plant and equipment	2,420.80	2,545.88
(b) Financial assets		
(i) Investments	21.82	20.63
(ii) Other financial assets	80.09	80.69
(c) Other non-current assets	68.44	67.43
	2,591.14	2,714.64
Current assets		
(a) Inventories	5,668.15	4,997.06
(b) Financial assets		
(i) Trade receivables	433.09	1,324.71
(ii) Cash and cash equivalents	28.16	30.68
(iii) Bank balances other than (ii) above	37.29	36.23
(iv) Other financial assets	-	-
(c) Other current assets	306.64	350.71
	6,473.35	6,739.38
Total assets	9,064.49	9,454.01
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	921.90	921.90
(b) Other equity	500.20	542.86
	1,422.10	1,464.76
Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	646.78	378.59
(b) Provisions	124.21	80.43
(c) Deferred tax liabilities(Net)	81.00	91.34
	851.98	550.36
Current liabilities		
(a) Financial liabilities		
(i) Borrowings	3,631.35	3,626.12
(ii) Trade payables		
Total outstanding dues of micro and small enterprises;	829.37	621.99
Total outstanding dues of creditors other than micro and small enterprises	2,015.05	2,739.22
(iii) Other financial liabilities	11.98	5.22
(b) Other current liabilities	302.65	402.56
(c) Provisions	-	43.78
(d) Current tax liabilities (net)	-	-
	6,790.40	7,438.89
Total equity and liabilities	9,064.49	9,454.01

Date 08.11.2025
Place : Hyderabad.



For and on behalf of the Board

G. Venkata Ramana

G. Venkata Ramana
Managing Director
DIN: 00031873

Vineet Laboratories Limited

CIN:L24304TG2016PLC112888

Statement of Profit and Loss for the period ended 30 September 2025

(All amounts are in INR Lakhs except share data or unless otherwise stated)

Particulars	For the period ended	
	30 September 2025	31 March 2025
Income		
Revenue from operations	2,486.13	7,499.50
Other income	2.65	198.68
Total income	2,488.78	7,698.18
Expenses		
Cost of material consumed	2,909.87	6,376.84
Changes in inventories of stock-in -trade	(1267.05)	647.00
Employee benefits expense	185.61	533.58
Finance costs	279.92	397.76
Depreciation and amortisation expense	125.08	250.16
Other expenses	308.34	1,570.39
Total expenses	2,541.77	9,775.73
Profit Before Tax	(53.00)	(2077.55)
Tax expenses		
Current tax expense	-	-
Deferred tax expense	(6.49)	(58.45)
Taxes in respect of prior periods	-	-
Total tax expenses	(6.49)	(58.45)
Profit for the year	(46.51)	(2019.10)
Other Comprehensive Income ('OCI')		
(i) Items that will not be reclassified subsequently to profit or loss		
Re-measurement gains/(losses) on defined benefit plans	-	15.29
Income tax effect on the above	-	(3.85)
(ii) Items that will be reclassified subsequently to profit or loss		-
Total other comprehensive income	0.00	11.44
Total comprehensive income for the year	(46.51)	(2007.67)
Earnings per equity share (EPES)		
Basic EPS	(0.50)	(21.90)
Diluted EPS	(0.50)	(21.90)
Nominal value per equity share	10.00	10.00

Date 08.11.2025

Place : Hyderabad.



For and on behalf of the Board

G. Venkata Ramana
Managing Director
DIN: 00031873

G. Venkata Ramana
Managing Director

Independent Auditor's Review Report on the Quarterly and year to date Unaudited Financial Results of the Company pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors of **VINEET LABORATORIES LIMITED**

1. We have reviewed the accompanying statement of unaudited financial results of **VINEET LABORATORIES LIMITED** ('the Company') for the quarter ended 30th September 2025 and the year to date results for the period from 01st April 2025 to 30th September 2025 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations')
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of the regulation 33 of the SEBI (Listing Obligations and disclosure



NSVR & ASSOCIATES LLP

House No.1-89/1/42, 3rd Floor, Plot No. 41 & 43, Sri Ram Nagar Colony, Kavuri Hills, Guttala Begumpet, Madhapur, Hyderabad, Telangana - 500081. | Ph: 040 - 23391164, E-mail: info@nsvr.in

requirements) regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatements.


Our conclusion is not modified in respect of the above matters.

For NSVR & Associates LLP

Chartered Accountants

FRN: 008801S/200060

V. G. Gangadhara Rao N



V Gangadhara Rao N

Partner

Membership No: 219486

UDIN: 25219486BMISEJ2882

Place: Hyderabad

Date: 08-11-2025